Table 3 Base case results of the cost-effectiveness analysis. LYs, life years, QALYs, qualityadjusted life years, ICER, incremental cost-effectiveness ratio.

From: Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Outcomes

Palbociclib plus fulvestrant

Ribociclib plus fulvestrant

Abemaciclib plus fulvestrant

LYs

4.00

4.91

4.55

QALYs

2.10

2.55

2.60

Cost, $

34,423

41,119

48,019

Incremental cost, $

–

6696

13,596

Incremental LYs

–

0.91

0.55

Incremental QALYs

–

0.44

0.50

ICER, $

–

15,073

27,161

ICER (abemaciclib vs.

ribociclib), $

–

–

123,215

Back to article page